Entrada Therapeutics TRDA Ratios (2021-2026)

NASDAQ TRDA
$7.13 -0.04 (-0.56%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Entrada Therapeutics Quarterly Ratios

Periods 19 quarters
Latest Jun 2026

Entrada Therapeutics reported a net margin of -4,762.03% for the quarter ended Jun 2026. These financial ratios cover 19 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin -12.36%-66.49%41.30%22.08%42.84%61.03%-81.21%-1.94%-84.39%-2,201.28%-2,693.93%-3,007.85%-4,534.74%-4,758.13%
EBIT Margin -22.88%-89.70%32.04%11.72%35.71%56.42%-110.67%-15.69%-105.99%-2,402.51%-2,915.18%-3,249.27%-4,834.63%-5,007.02%
EBITDA Margin -22.88%-89.70%32.04%11.72%35.71%56.42%-110.67%-15.69%-105.99%-2,402.51%-2,915.18%-3,249.27%-4,834.63%-5,007.02%
Operating Margin -22.88%-89.70%32.04%11.72%35.71%56.42%-110.67%-15.69%-105.99%-2,402.51%-2,915.18%-3,249.27%-4,834.63%-5,007.02%
Net Margin -26.62%-142.70%81.09%-22.70%39.74%58.07%-71.50%2.95%-84.39%-2,210.41%-2,737.30%-3,014.93%-4,539.09%-4,762.03%
FCF Margin 771.05%-196.86%-61.59%-9.13%-44.58%45.11%-147.33%-86.21%-192.87%-1,526.36%-1,743.62%-2,463.13%-4,770.17%-3,616.26%
Efficiency
Assets AverageAssets Avg. 219.11M311.27M306.31M285.19M263.26M363.81M484.78M489.51M477.11M490.02M546.40M568.28M540.46M506.40M467.63M430.84M395.14M356.45M317.20M
Asset Utilization RatioAsset Util. 0.070.090.180.270.330.440.380.390.340.170.140.060.020.01
Valuation
Price to EarningsP/E -5.82-13.55-16.44-19.64-17.23-71.46-19.3914.85-53.1120.279.63-42.71587.93-19.77-5.93-5.02-10.05-12.34-6.70
Price to SalesP/S 19.0227.6712.0412.068.055.5930.5417.3716.68131.07137.34302.97559.90319.12
Price to BookP/B 0.361.061.492.122.002.092.432.142.081.771.231.411.520.820.670.651.291.811.23
Enterprise Value -183.76M29.67M136.79M278.12M379.30M252.79M422.99M474.89M436.97M407.73M344.46M519.61M548.45M275.16M183.11M128.39M302.51M413.47M187.29M
EV to EBIT 9.95-1.34-5.80-10.72-14.83-43.74-25.9533.8989.0919.316.45-23.99-93.48-12.63-3.91-2.73-7.17-9.77-4.17
EV to EBITDA 9.95-1.34-5.80-10.72-14.83-43.74-25.9533.8989.0919.316.45-23.99-93.48-12.63-3.91-2.73-7.17-9.77-4.17
Market Capitalization 107.30M293.57M381.04M493.69M424.46M480.44M502.73M526.78M504.57M476.17M529.71M597.66M649.66M343.00M255.59M221.67M393.56M489.92M286.57M
Price to FCFP/FCF -4.91-13.60-20.29-17.45-14.412.47-14.06-19.56-132.02-18.0712.40-20.73-20.15-8.65-8.59-7.88-12.30-11.74-8.82
EV to FCF 8.41-1.37-7.28-9.83-12.871.30-11.83-17.63-114.33-15.478.06-18.02-17.01-6.94-6.15-4.56-9.45-9.91-5.77
EV to CFO 8.95-1.41-7.60-10.12-13.891.24-12.05-19.39-108.89-15.988.65-21.41-17.35-7.15-6.21-4.53-9.39-9.92-5.77
Return Ratios
Return on Sales [ROS]ROS -22.88%-89.70%32.04%11.72%35.71%56.42%-110.67%-15.69%-105.99%-2,402.51%-2,915.18%-3,249.27%-4,834.63%-5,007.02%
Return on Capital Employed [ROCE]ROCE -24.07%-21.93%-27.25%-34.19%-40.30%-37.41%-20.51%-10.38%-0.99%7.51%20.29%11.61%9.38%0.84%-21.47%-29.88%-42.60%-52.90%-59.67%
Return on Assets [ROA]ROA -23.35%-20.71%-25.38%-31.01%-35.94%-21.90%-17.00%-4.46%-1.40%4.80%19.12%9.68%12.14%4.89%-15.68%-24.03%-36.39%-46.62%-52.28%